PCSK9 and chronic kidney disease: In addition, future research should focus on several practical areas, such as long-term, randomized trials with PCSK9 inhibitors specifically in advanced stages of CKD, investigation of their effects on kidney function, such as GFR decline and proteinuria, assessing cost-effectiveness in CKD populations, and investigating potential interactions with new lipid-lowering therapies.